Mo Bidair

Los Angeles Clinical Trials

Papers

4

Total Citations

100

H-Index

3

About

Dr. Mo Bidair is a leading urologic surgeon and researcher whose work has fundamentally reshaped the surgical management of benign prostatic hyperplasia (BPH), particularly for patients with large-volume prostates. His primary research focus is the development and validation of Aquablation therapy, a minimally invasive, robotically executed waterjet ablation technique. Dr. Bidair’s landmark contributions include serving as the principal investigator for the pivotal WATER and WATER II clinical trials. His most cited work, the 5-year results of the WATER II trial (49 citations), demonstrated that Aquablation provides durable, safe, and effective relief from lower urinary tract symptoms in men with prostates ranging from 80 to 150 mL—a population historically limited to more invasive open surgery. He further showed that this technology offers a superior sexual function preservation profile compared to traditional transurethral resection of the prostate (TURP). By providing robust, long-term evidence for a novel, less invasive alternative, Dr. Bidair’s research has directly expanded treatment options for a challenging patient demographic, establishing him as a key innovator in the evolution of BPH surgery.

Research Focus

Key Achievements

3
H-Index
4
Papers
100
Total Citations
25
Avg Citations/Paper
🏆 Most Cited Paper
Aquablation Therapy in Large Prostates (80-150 mL) for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Final WATER II 5-Year Clinical Trial Results
49 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 33
🏛 Institutions: Los Angeles Clinical Trials

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago